Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

NYU Langone Medical Center announced today the U.S. Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sandra and Edward Meyer Professor and Chair of the Department of Radiation Oncology a $4.5 million Multi-Team Award to conduct novel breast cancer research.

21 Apr 2011

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

20 Apr 2011

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

19 Apr 2011

Study finds more evidence linking high-grade serous ovarian cancer to fallopian tubes

High-grade serous ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, is thought by many scientists to often be a fallopian tube malignancy masquerading as an ovarian one. While most of the evidence linking HGSOC to the fallopian tubes has so far been only circumstantial, a new Dana-Farber Cancer Institute study suggests there is a direct connection, a finding that could aid in the development of better treatments for the cancer.

19 Apr 2011

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

16 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Protest over planned cuts to Australian medical research funding

Australian medical researchers are protesting around the country following reports that funding to the sector could be cut in the May budget. The federal government is considering slashing $400 million from medical research.

11 Apr 2011

New treatment approach raises hope for women with ovarian cancer

Researchers at Oregon Health & Science University's Oregon National Primate Research Center may have good news for women at high-risk for ovarian cancer who also want to have children.

8 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

AACR President-elect to host press conference on cancer risk factors and genetics

As cancer continues to affect one in two men and one in three women, researchers are increasing their knowledge on the known risk factors for cancer both environmentally and genetically.

5 Apr 2011

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.

5 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

Longer Looks: Behind the hospital money curtain; Medical data breaches

Think you would stick to a diet if someone paid you for it? Would you be more likely to exercise if you were fined each time you bailed on your scheduled workout? Research in recent years suggests—and a handful of new businesses are betting—that you might.

25 Mar 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

Study finds more evidence linking high-grade serous ovarian cancer to fallopian tubes

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

Major pharmaceutical company, Access sign deal for RNAi therapeutics

Protest over planned cuts to Australian medical research funding

New treatment approach raises hope for women with ovarian cancer

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

AACR President-elect to host press conference on cancer risk factors and genetics

Women with ovarian cancer having BRCA2 gene mutations are more likely to survive

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

Longer Looks: Behind the hospital money curtain; Medical data breaches

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in